Clinical Trials List
Protocol NumberTED16132
Completed
2020-12-21 - 2023-12-31
Phase I
Recruiting2
-
Trial Applicant
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/01
Investigators and Locations
Co-Principal Investigator
- Ming-Yu Lien Division of Hematology & Oncology
- Chi-Ching Chen Division of Hematology & Oncology
- Che-Hung Lin Division of Hematology & Oncology
- Ching-Chan Lin Division of Hematology & Oncology
- Ching Yun Hsieh Division of Hematology & Oncology
- Ming-Hung Tsai Division of Hematology & Oncology
- Chen-Yuan Lin Division of Hematology & Oncology
- Tzu-Ting Chen Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- MING YAO Division of Hematology & Oncology
- Shang-Ju Wu Division of Hematology & Oncology
- Tai-Chung Huang Division of Hematology & Oncology
- Huai-Hsuan Huang Division of Hematology & Oncology
- - - Division of Hematology & Oncology
- Chien-Chin Lin Division of Hematology & Oncology
- Shang-Yi Huang Division of Hematology & Oncology
- Sheng-chieh Chou Division of Hematology & Oncology
- 田豐銘 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
10 participants
-
Global
95 participants
